BridgeBio Pharma (BBIO) is likely to see a continuation of its share outperformance as sales of Attruby, its FDA-approved treatment for transthyretin amyloid cardiomyopathy, beat consensus estimates, Oppenheimer said in a note Wednesday.

The investment firm said its Attruby Q2 and full-year sales estimates of $76 million and $374 million are "well above" consensus forecasts and may even "prove conservative given our assumptions around flat monthly script growth and high rates of free scripts."

Oppenheimer also expects BridgeBio's "commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials" around the end of the year.

The firm said it still has some concerns related to "long-term revenue durability," but the company has time to show "real-world datasets demonstrating benefit over tafamidis should generics become available in 2029."

Meanwhile, BridgeBio also faces some risks linked to ongoing tafamidis PTE litigation, but "timelines suggest earliest resolution of 1Q28," according to the note.

Oppenheimer raised its rating on BridgeBio Pharma to outperform, with a price target of $60.

Price: 44.87, Change: +1.68, Percent Change: +3.89